Loading patent…
AssigneeThe Salk Institute for Biological Studies
InventorsRonald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
Estimating the term…
In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
A composition in unit dosage form for oral administration consisting essentially of as an active ingredient a compound selected from the group consisting of 9-cis retinoic acid, pharmaceutically acceptable salts thereof, pharmaceutically acceptable hydrolyzable esters thereof and a pharmaceutically acceptable carrier suitable for oral administration.
A composition in unit dosage form for oral administration consisting of as an active ingredient a compound selected from the group consisting of 9-cis retinoic acid, pharmaceutically acceptable salts thereof, pharmaceutically acceptable hydrolyzable esters thereof and a pharmaceutically acceptable carrier suitable for oral administration.
Dependencies are inferred from the claim text.